These studies indicate that CLRs may also utilize the classical SYK/CARD9 pathway to induce the expansion of CD8+ T cells in the tumor microenvironment in bladder cancer and thus influence ICB therapy efficacy. The gene discussed is CD8A; the disease is urinary bladder carcinoma.